bioAffinity Licenses CyPath® Lung to Precision Pathology Services
10 oct. 2018 12h00 HE
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Oct. 10, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced a licensing agreement with Precision Pathology Services for the continued...
Mount Sinai Joins Test Validation Trial of bioAffinity’s CyPath® Lung
18 sept. 2018 14h00 HE
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Sept. 18, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced that the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY,...
bioAffinity Technologies Announces $4 Million Series A Funding
19 juil. 2017 15h00 HE
|
bioAffinity Technologies, Inc.
SAN ANTONIO, July 19, 2017 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held company advancing early-stage cancer diagnostics and precision therapeutics, announced today that it raised...
City of San Antonio Invests in bioAffinity Technologies
09 mars 2017 19h02 HE
|
bioAffinity Technologies, Inc.
SAN ANTONIO, March 09, 2017 (GLOBE NEWSWIRE) -- The San Antonio City Council today authorized the San Antonio Economic Development Corporation (SAEDC) to invest in locally based bioAffinity...